Headlines

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

Published by Global Banking & Finance Review

Posted on February 24, 2025

1 min read

· Last updated: January 25, 2026

Add as preferred source on Google
Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list
Global Banking & Finance Awards 2026 — Call for Entries

(Reuters) - Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its

Compounders Challenge FDA's Decision on Wegovy and Ozempic Shortage

(Reuters) - Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's weight loss and diabetes drugs Wegovy and Ozempic from its shortage list, a move that will sharply curtail the compounders' ability to sell cheaper versions of the drugs.

(Reporting By Brendan Pierson in New York; Editing by Leslie Adler)

Key Takeaways

  • Drug compounders filed a lawsuit against the FDA.
  • FDA removed Wegovy and Ozempic from the shortage list.
  • The decision affects compounders' ability to sell cheaper versions.
  • Novo Nordisk's drugs are central to the lawsuit.
  • The lawsuit could impact the availability of affordable drugs.

Frequently Asked Questions

What drugs are involved in the lawsuit against the FDA?
The lawsuit involves Novo Nordisk's weight loss and diabetes drugs, Wegovy and Ozempic.
Why did the drug compounders sue the FDA?
They sued the FDA over its decision to remove Wegovy and Ozempic from its shortage list.
Who reported on the lawsuit?
The article was reported by Brendan Pierson in New York, with editing by Leslie Adler.

Tags

Related Articles

More from Headlines

Explore more articles in the Headlines category